These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32378586)

  • 1. [Molecular mechanisms by which the mutant ASXL1/BAP1 complex aggravates myeloid leukemia].
    Asada S
    Rinsho Ketsueki; 2020; 61(4):392-405. PubMed ID: 32378586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
    Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
    Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
    Balasubramani A; Larjo A; Bassein JA; Chang X; Hastie RB; Togher SM; Lähdesmäki H; Rao A
    Nat Commun; 2015 Jun; 6():7307. PubMed ID: 26095772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
    Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
    Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
    Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
    Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.
    Thomas JF; Valencia-Sánchez MI; Tamburri S; Gloor SL; Rustichelli S; Godínez-López V; De Ioannes P; Lee R; Abini-Agbomson S; Gretarsson K; Burg JM; Hickman AR; Sun L; Gopinath S; Taylor HF; Sun ZW; Ezell RJ; Vaidya A; Meiners MJ; Cheek MA; Rice WJ; Svetlov V; Nudler E; Lu C; Keogh MC; Pasini D; Armache KJ
    Sci Adv; 2023 Aug; 9(32):eadg9832. PubMed ID: 37556531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
    Wang L; Birch NW; Zhao Z; Nestler CM; Kazmer A; Shilati A; Blake A; Ozark PA; Rendleman EJ; Zha D; Ryan CA; Morgan MAJ; Shilatifard A
    Nat Cancer; 2021 May; 2(5):515-526. PubMed ID: 35122023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of histone H2A lysine 119 deubiquitination by Polycomb Repressive Deubiquitinase BAP1/ASXL1.
    Thomas JF; Valencia-Sánchez MI; Tamburri S; Gloor SL; Rustichelli S; Godínez-López V; De Ioannes P; Lee R; Abini-Agbomson S; Gretarsson K; Burg JM; Hickman AR; Sun L; Gopinath S; Taylor H; Meiners MJ; Cheek MA; Rice W; Nudler E; Lu C; Keogh MC; Pasini D; Armache KJ
    bioRxiv; 2023 Feb; ():. PubMed ID: 36865140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of BAP1 function leads to EZH2-dependent transformation.
    LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
    Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
    Takeda R; Asada S; Park SJ; Yokoyama A; Becker HJ; Kanai A; Visconte V; Hershberger C; Hayashi Y; Yonezawa T; Tamura M; Fukushima T; Tanaka Y; Fukuyama T; Matsumoto A; Yamasaki S; Nakai K; Yamazaki S; Inaba T; Shibata T; Inoue D; Honda H; Goyama S; Maciejewski JP; Kitamura T
    Blood; 2020 Oct; 136(14):1670-1684. PubMed ID: 32492700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
    Abdel-Wahab O; Dey A
    Leukemia; 2013 Jan; 27(1):10-5. PubMed ID: 23147254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.
    Daou S; Hammond-Martel I; Mashtalir N; Barbour H; Gagnon J; Iannantuono NV; Nkwe NS; Motorina A; Pak H; Yu H; Wurtele H; Milot E; Mallette FA; Carbone M; Affar el B
    J Biol Chem; 2015 Nov; 290(48):28643-63. PubMed ID: 26416890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1.
    Daou S; Barbour H; Ahmed O; Masclef L; Baril C; Sen Nkwe N; Tchelougou D; Uriarte M; Bonneil E; Ceccarelli D; Mashtalir N; Tanji M; Masson JY; Thibault P; Sicheri F; Yang H; Carbone M; Therrien M; Affar EB
    Nat Commun; 2018 Oct; 9(1):4385. PubMed ID: 30349006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retracted: Histone H2B ubquitination regulates retinoic acid signaling through the cooperation of ASXL1 and BAP1.
    Lee SW; Youn H; Kim EJ; Um SJ
    Mol Cell; 2013 Jul; 51(2):200-10. PubMed ID: 23850490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Expression Analysis of Pediatric Acute Myeloid Leukemia Identified a Hyperactive ASXL1/BAP1 Axis Linked with Poor Prognosis and over Expressed Epigenetic Modifiers.
    Elyamany G; Akhter A; Kamran H; Rizwan H; Shabani-Rad MT; Alkhayat N; Al Sharif O; Elborai Y; Al Shahrani M; Mansoor A
    Pediatr Hematol Oncol; 2021 Sep; 38(6):581-592. PubMed ID: 33764257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of the tumor suppressor BAP1 causes myeloid transformation.
    Dey A; Seshasayee D; Noubade R; French DM; Liu J; Chaurushiya MS; Kirkpatrick DS; Pham VC; Lill JR; Bakalarski CE; Wu J; Phu L; Katavolos P; LaFave LM; Abdel-Wahab O; Modrusan Z; Seshagiri S; Dong K; Lin Z; Balazs M; Suriben R; Newton K; Hymowitz S; Garcia-Manero G; Martin F; Levine RL; Dixit VM
    Science; 2012 Sep; 337(6101):1541-6. PubMed ID: 22878500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
    Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
    Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial and Somatic
    Peng H; Prokop J; Karar J; Park K; Cao L; Harbour JW; Bowcock AM; Malkowicz SB; Cheung M; Testa JR; Rauscher FJ
    Cancer Res; 2018 Mar; 78(5):1200-1213. PubMed ID: 29284740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ASXL1 in hematopoiesis and myeloid malignancies.
    Asada S; Fujino T; Goyama S; Kitamura T
    Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.